KR100466693B1 - A preparing process of phenoxyacetamide derivative - Google Patents
A preparing process of phenoxyacetamide derivative Download PDFInfo
- Publication number
- KR100466693B1 KR100466693B1 KR10-2002-0044333A KR20020044333A KR100466693B1 KR 100466693 B1 KR100466693 B1 KR 100466693B1 KR 20020044333 A KR20020044333 A KR 20020044333A KR 100466693 B1 KR100466693 B1 KR 100466693B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compound
- phenoxyacetamide
- derivative
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
본 발명은 페녹시아세트아미드 유도체의 제조방법에 관한 것으로, 하기 화학식 3으로 표현되는 화합물을 탈 할로겐화 반응시키는 페녹시아세트아미드 유도체의 제조방법을 제공한다. .The present invention relates to a method for producing a phenoxyacetamide derivative, and provides a method for producing a phenoxyacetamide derivative by dehalogenation reaction of a compound represented by the following formula (3). .
<화학식 1><Formula 1>
<화학식 3><Formula 3>
상기 화학식 3에서 X는 Cl, Br 또는 I를 나타낸다.In Formula 3, X represents Cl, Br or I.
Description
본 발명은 페녹시아세트아미드 유도체의 제조방법에 관한 것으로, 보다 상세하게는 하기 화학식 1로 표현되는 5-[2-(2-에톡시페녹시)아세트아미노]프로필-2-메톡시벤젠설폰아미드를 간단한 반응공정을 통해 높은 수율로 얻을 수 있도록 한 페녹시아세트아미드 유도체의 제조방법에 관한 것이다.The present invention relates to a process for the preparation of phenoxyacetamide derivatives, more particularly 5- [2- (2-ethoxyphenoxy) acetamino] propyl-2-methoxybenzenesulfonamide represented by the following formula (1): It relates to a method for preparing a phenoxyacetamide derivative which can be obtained in a high yield through a simple reaction process.
상기 화학식 1의 페녹시아미드 유도체 화합물은 하기 화학식 2의 펜에틸아민 화합물의 유도체 화합물이며, 화학식 1의 화합물을 환원반응시킨후 산부가하면 화학식 2의 화합물이 얻어진다. 화학식 2의 화합물은 일명 탐술로신으로 α-아드레날린성 차단 작용을 나타내며, 양성 전립선 비대, 항고혈압제 및 울혈성 심부전의 치료제로 유용하게 사용되는 화합물이다.The phenoxyamide derivative compound of Formula 1 is a derivative compound of the phenethylamine compound of Formula 2 below, and when the acid is added after reduction of the compound of Formula 1, a compound of Formula 2 is obtained. Compound of the formula (2) is a so called tamsulosin, a α-adrenergic blocking action, is a compound useful for the treatment of benign prostatic hypertrophy, antihypertensives and congestive heart failure.
상기 화학식 1의 페녹시아세트아미드 유도체 화합물을 제조하기 위한 방법으로 일본 특허 제 2295967호 및 일본 특허 제 2306958호에서는 하기 반응식 1에 나타낸 바와 같이 할로아세트아미드 화합물을 알콕시페놀 유도체 화합물과 반응시켜 제조하는 방법을 개시하고 있다.As a method for preparing the phenoxyacetamide derivative compound of Chemical Formula 1, Japanese Patent No. 2295967 and Japanese Patent No. 2306958 prepare a method by reacting a haloacetamide compound with an alkoxyphenol derivative compound as shown in Scheme 1 below. Is starting.
상기 반응식 1에서 R1은 저급 알킬기이며, R2는 수소원자 또는 할로겐이고, X는 Br, CH3SO3-이다.In Scheme 1, R 1 is a lower alkyl group, R 2 is a hydrogen atom or a halogen, X is Br, CH 3 SO 3-.
그러나, 상기한 방법은 알콕시페놀 유도체 화합물이 할로아세트아미드 화합물의 설폰아미드기와도 반응할 수 있어 목적 생성물과는 전혀 다른 부산물이 생길 수 있으므로(Jerry March., Advanced organic chemistry., 3rd edition., P 378), 그 수율이 더욱 낮아지는 문제점이 있다.However, the above-described method may react with the sulfonamide group of the haloacetamide compound of the alkoxyphenol derivative compound, so that a by-product which is completely different from the desired product may be produced (Jerry March., Advanced organic chemistry., 3rd edition., P.). 378) There is a problem that the yield is further lowered.
그에 따라 화학식 1의 화합물을 제조하는 과정에서 부반응을 억제하여 공정의 수율을 극대화할 수 있는 페녹시아세트아미드 유도체의 제조방법 개발이 절실히요구되었다.Accordingly, there is an urgent need to develop a method for preparing a phenoxyacetamide derivative capable of maximizing the yield of the process by inhibiting side reactions in the process of preparing the compound of Formula 1.
본 발명자들은 상기와 같은 종래 기술의 문제점을 해결하기 위하여 예의 노력한 결과, 반응공정 중 부반응을 수반하지 않으면서 간단한 반응공정으로 상기 화학식 1의 화합물을 고수율로 얻을 수 있는 방법을 개발하였다.The present inventors have made diligent efforts to solve the problems of the prior art, and as a result, have developed a method of obtaining the compound of Formula 1 in a high yield in a simple reaction process without involving side reactions in the reaction process.
이에 본 발명의 주목적은 상기 화학식 1의 페녹시아세트아미드 유도체 화합물을 간단한 반응공정으로 부반응을 수반하지 않으면서 높은 수율로 얻을 수 있는 페녹시아세트아미드 유도체의 제조방법을 제공하는데 있다.Accordingly, the main object of the present invention is to provide a method for preparing a phenoxyacetamide derivative which can be obtained in high yield without involving side reactions in a simple reaction process of the phenoxyacetamide derivative compound of Formula 1.
상기한 목적을 달성하기 위하여 본 발명은The present invention to achieve the above object
하기 화학식 3으로 표현되는 화합물을 탈 할로겐화 반응시켜 화학식 1의 페녹시아세트아미드 유도체 화합물을 제조하는 것을 특징으로 하는 페녹시아세트아미드 유도체의 제조방법을 제공한다.Provided is a method for producing a phenoxyacetamide derivative, characterized in that to produce a phenoxyacetamide derivative compound of formula (1) by a dehalogenation reaction of the compound represented by the formula (3).
<화학식 1><Formula 1>
상기 화학식 3에서 X는 Cl, Br 또는 I를 나타낸다.In Formula 3, X represents Cl, Br or I.
이하, 본 발명에 따른 화학식 1의 페녹시아세트아미드 유도체 제조방법을 보다 구체적으로 설명하면 다음과 같다.Hereinafter, a method for preparing the phenoxyacetamide derivative of Formula 1 according to the present invention will be described in more detail.
본 발명은 화학식 3으로 표현되는 화합물을 탈 할로겐화시켜 화학식 1의 페녹시아세트아미드 유도체를 제조하는 방법에 관한 것으로서, 본 발명에서 사용되는 화학식 3의 화합물은 타이로신을 출발물질로하여 쉽게 제조될 수 있는 화합물로서 국내 특허출원번호 제2001-24696호에 상세하게 기재되어 있다.The present invention relates to a method for preparing a phenoxyacetamide derivative of formula (1) by de-halogenating the compound represented by formula (3), wherein the compound of formula (3) used in the present invention can be easily prepared using tyrosine as a starting material. It is described in detail in Korean Patent Application No. 2001-24696 as a compound.
탈 할로겐화반응은 유기용매하에서 화학식 3의 화합물을 환원제와 반응시키는 것으로서, 상기 용매는 테트라히드로퓨란 또는 1,4-디옥산에서 선택되는 에테르 용매를 사용하거나 헥사메칠포스포트리아미드(HMPA)를 사용할 수 있으며, 환원제는 아연이나 소듐보로하이드라이드에서 선택된 것을 사용할 수 있다.The dehalation reaction is a reaction of the compound of Formula 3 with a reducing agent in an organic solvent, and the solvent may be an ether solvent selected from tetrahydrofuran or 1,4-dioxane or hexamethylphosphotriamide (HMPA). The reducing agent may be selected from zinc or sodium borohydride.
용매와 환원제는 출발물질에 따라 적당한 것을 선택하여 사용하는 것이 좋다.The solvent and reducing agent may be selected and used appropriately depending on the starting materials.
예를 들어 화학식 3으로 표현되는 화합물에서 X가 I인 하기 화학식 4의 요오드알킬페녹시아세트아미드 화합물의 경우 탈할로겐화 반응은 다음과 같이 진행되는 것이 바람직하다.For example, in the case of the iodine alkylphenoxyacetamide compound of Formula 4, wherein X is I in the compound represented by Formula 3, the dehalogenation reaction is preferably performed as follows.
테트라히드로퓨란 또는 1,4-디옥산에서 선택되는 에테르 용매하에서 화학식 4의 요오드알킬페녹시아세트아미드 화합물을 아연과 환류반응시키는 것이다.A reflux reaction of the iodinealkylphenoxyacetamide compound of formula 4 with zinc is carried out in an ether solvent selected from tetrahydrofuran or 1,4-dioxane.
상기 반응시 환원제인 아연의 첨가량은 요오드알킬페녹시아세트아미드 화합물 1당량에 대하여 1.1당량 이상 첨가하면 되는데, 바람직한 첨가량은 요오드알킬페녹시아세트아미드 화합물 1당량에 대하여 1∼3당량 첨가하는 것이 좋다.In the reaction, the addition amount of zinc as a reducing agent may be added at least 1.1 equivalents to 1 equivalent of the iodine alkylphenoxyacetamide compound, but preferably 1 to 3 equivalents is added based on 1 equivalent of the iodine alkylphenoxyacetamide compound.
환류반응시간은 30분 이상 실시하면 충분하고, 환류반응 후 반응물을 냉각하고 농축한 다음, 여기에 클로로포름을 가한 후 염산수용액으로 충분히 세척한 다음 감압 증류하면 화학식 1의 화합물을 얻을 수 있게 된다.The reflux reaction time is more than 30 minutes is sufficient, after the reflux reaction, the reaction product is cooled and concentrated, chloroform is added thereto, washed sufficiently with aqueous hydrochloric acid solution and then distilled under reduced pressure to obtain the compound of formula (1).
이때, 탈할로겐화 반응시 부반응 방지를 위하여 포름산 또는 아세트산에서 선택되는 저급알킬카르복실산이나 벤조산, 페닐아세트산 또는 만델산에서 선택되는 카르복실산을 더 첨가하여 탈할로겐화 반응을 진행하는 것이 바람직하다.In this case, in order to prevent side reactions during the dehalogenation reaction, it is preferable to further proceed with the dehalogenation reaction by further adding a lower alkylcarboxylic acid selected from formic acid or acetic acid or a carboxylic acid selected from benzoic acid, phenylacetic acid or mandelic acid.
2-에톡시페녹시아세트아미드와 3-(3-아미노설포닐-4-메톡시페닐)-1-프로필렌이 생성되는 부반응 방지를 위한 카르복시산의 첨가량은 0.5당량이상 사용되며 메카니즘은 알킬아연요오드(RZnI)의 생성억제에 관여하는 것으로 추정된다.The amount of carboxylic acid added to prevent side reactions in which 2-ethoxyphenoxyacetamide and 3- (3-aminosulfonyl-4-methoxyphenyl) -1-propylene is produced is used in an amount of 0.5 equivalent or more, and the mechanism is alkyl zinc iodine ( It is presumed to be involved in production inhibition of RZnI).
또, 화학식 3으로 표현되는 화합물에서 X가 Br인 하기 화학식 5의 브로모알킬페녹시아세트아미드 화합물인 경우와, X가 Cl인 하기 화학식 6의 클로르알킬페녹시아세트아미드 화합물인 경우 탈할로겐화 반응은 다음과 같이 실시하는 것이 바람직하다.In the compound represented by the formula (3), the dehalogenation reaction in the case of the bromoalkylphenoxyacetamide compound of formula (5) wherein X is Br and the chloralkylphenoxyacetamide compound of formula (6) wherein X is Cl is It is preferable to carry out as follows.
헥사메칠포스포트리아미드(HMPA) 용매하에서 화학식 5의 브로모알킬페녹시아세트아미드 화합물 또는 화학식 6의 클로르알킬페녹시아세트아미드 화합물을 소디움보로하이드라이드와 60∼100℃, 더욱 바람직하기로는 70∼80℃에서 반응시키는 것이다.The bromoalkylphenoxyacetamide compound of formula (5) or the chloralkylphenoxyacetamide compound of formula (6) is reacted with sodium borohydride at 60-100 ° C., more preferably 70-70, in hexamethylphosphotriamide (HMPA) solvent. It is made to react at 80 degreeC.
상기 반응시 환원제인 소듐보로하이드라이드의 첨가량은 브로모알킬페녹시아세트아미드 화합물 또는 클로로알킬페녹시아세트아미드 화합물 1당량에 대하여 1.1당량 이상 첨가하면 되는데, 바람직한 첨가량은 브로모알킬페녹시아세트아미드 화합물 또는 클로로알킬페녹시아세트아미드 화합물 1당량에 대하여 1∼10당량 첨가하는 것이 좋다.In the reaction, the amount of sodium borohydride which is a reducing agent may be added in an amount of 1.1 equivalent or more based on 1 equivalent of the bromoalkylphenoxyacetamide compound or the chloroalkylphenoxyacetamide compound, and the preferred amount is preferably bromoalkylphenoxyacetamide. It is preferable to add 1-10 equivalents with respect to 1 equivalent of the compound or the chloroalkylphenoxyacetamide compound.
반응시간은 2시간 이상이면 충분하고, 반응 후 서서히 5% 염산 수용액을 가한 다음 클로르포름으로 2회이상 추출 후 추출물을 건조 농축하고, 상기 농축물을 이소프로필알코올로 재결정하면 화학식 1의 화합물을 얻을 수 있게 된다.The reaction time is more than 2 hours is sufficient, after the reaction is slowly added 5% aqueous hydrochloric acid solution, extracted with chloroform two or more times, the extract is concentrated to dryness, and recrystallized the concentrate with isopropyl alcohol to obtain a compound of formula 1 Will be.
상술한 바와 같이 화학식 3으로 표현되는 화합물을 출발물질로 하고, 이를용매하에서 환원제와 반응시킬 경우 부반응이 억제되어 부산물의 발생을 억제할 수 있을 뿐만 아니라 용이하게 화학식 1의 화합물을 높은 수율로 얻을 수 있게 된다.As described above, when the compound represented by the formula (3) is used as a starting material and reacted with a reducing agent in a solvent, side reactions are suppressed to suppress the generation of by-products, and the compound of the formula (1) can be easily obtained in high yield. Will be.
이하, 바람직한 실시예를 통하여 본 발명에 의한 제조방법을 상세히 설명하기로 하나, 이는 본 발명을 구체적으로 설명하기 위한 것일 뿐, 본 발명이 이에 한정되는 것은 아니다.Hereinafter, the manufacturing method according to the present invention will be described in detail with reference to preferred embodiments, which is only for describing the present invention in detail, but the present invention is not limited thereto.
<제조예 1> 화학식 4의 (S)-5-[2-(2-에톡시페녹시)아세트아미노-3-요오도]프로필-2-메톡시벤젠설폰아미드의 제조Preparation Example 1 Preparation of (S) -5- [2- (2-ethoxyphenoxy) acetamino-3-iodo] propyl-2-methoxybenzenesulfonamide of Chemical Formula 4
(S)-5-[2-(2-에톡시페녹시)아세트아미노-3-하이드록시]프로필-2-메톡시벤젠설폰아미드 109.7g, 1,4-디옥산 1100ml, 트리페닐포스핀 72.1g 및 요오드 69.9g을 가하고, 이를 3시간동안 환류교반하였다. 상기 반응물을 농축한 후, 메탄올에서 교반하고 여과하여 화학식 4의 (S)-5-[2-(2-에톡시페녹시)아세트아미노-3-요오도]프로필-2-메톡시벤젠설폰아미드 117.8g을 수득하였다.109.7 g of (S) -5- [2- (2-ethoxyphenoxy) acetamino-3-hydroxy] propyl-2-methoxybenzenesulfonamide, 1100 ml of 1,4-dioxane, triphenylphosphine 72.1 g and 69.9 g of iodine were added and stirred at reflux for 3 hours. The reaction was concentrated, stirred in methanol and filtered to give (S) -5- [2- (2-ethoxyphenoxy) acetamino-3-iodo] propyl-2-methoxybenzenesulfonamide of formula (4). 117.8 g was obtained.
수득된 화합물의 mp와 NMR 데이터는 다음과 같다.Mp and NMR data of the obtained compound are as follows.
mp : 164-166℃,mp: 164-166 ° C.,
1H-NMR(CDCl3) δ: 1.50 (3H, t), 2.90 (2H, d), 3.15-3.50 (2H, dd), 4.00 (3H, s), 4.05-4.20 (3H, m), 4.50 (2H, s) 1 H-NMR (CDCl 3 ) δ: 1.50 (3H, t), 2.90 (2H, d), 3.15-3.50 (2H, dd), 4.00 (3H, s), 4.05-4.20 (3H, m), 4.50 (2H, s)
<제조예 2> 화학식 6의 (S)-5-[2-(2-에톡시페녹시)아세트아미노-3-클로로]프로필-2-메톡시벤젠설폰아미드의 제조Preparation Example 2 Preparation of (S) -5- [2- (2-ethoxyphenoxy) acetamino-3-chloro] propyl-2-methoxybenzenesulfonamide of Chemical Formula 6
(S)-5-[2-(2-에톡시페녹시)아세트아미노-3-하이드록시]프로필-2-메톡시벤젠설폰아미드 4.83g, 메틸렌 클로라이드 25ml 및 티오닐 클로라이드 0.91ml를 혼합하고, 이를 상온에서 밤새 교반한 후, 다시 30분 동안 환류 교반하였다. 상기 반응물을 농축한 후, 에틸 아세테이트에서 교반하고 여과하여 화학식 6의 (S)-5-[2-(2-에톡시페녹시)아세트아미노-3-클로로]프로필-2-메톡시벤젠설폰아미드 4.68g을 수득하였다.4.83 g of (S) -5- [2- (2-ethoxyphenoxy) acetamino-3-hydroxy] propyl-2-methoxybenzenesulfonamide, 25 ml of methylene chloride and 0.91 ml of thionyl chloride are mixed, After stirring at room temperature overnight, the mixture was stirred under reflux for another 30 minutes. The reaction was concentrated, stirred in ethyl acetate and filtered to give (S) -5- [2- (2-ethoxyphenoxy) acetamino-3-chloro] propyl-2-methoxybenzenesulfonamide of formula (6). 4.68 g were obtained.
수득된 화합물의 mp와 NMR 데이터는 다음과 같다.Mp and NMR data of the obtained compound are as follows.
mp : 164-166℃mp: 164-166 ° C
1H-NMR(CDCl3) δ: 1.50(3H, t), 2.95 (2H, d), 3.50-3.70 (2H, dd), 4.00 (3H, s), 4.10 (2H, q), 4.50 (3H, m) 1 H-NMR (CDCl 3 ) δ: 1.50 (3H, t), 2.95 (2H, d), 3.50-3.70 (2H, dd), 4.00 (3H, s), 4.10 (2H, q), 4.50 (3H , m)
<실시예 1><Example 1>
상기 제조예 1에서 수득한 (S)-5-[2-(2-에톡시페녹시)아세트아미노-3-요오드]프로필-2-메톡시벤젠설폰아미드 31.5g, 무수 테트라히드로퓨란 500ml, 아연 11.5g, 아세트산 4.65ml을 넣고 30분동안 환류 교반하였다. 이 반응용액을 셀라이트로 여과하고 클로르포름 150ml로 세척하였다. 여액을 농축한 다음 10% 염산 수용액 300ml를 가하고 클로로포름 300ml로 2회 추출, 건조, 농축하였으며, 상기 농축물을 이소프로필알코올로 재결정하여 화학식 1의 (R)-5-[2-(2-에톡시페녹시)아세트아미노]프로필-2-메톡시벤젠설폰아미드 22.1g(수율:91%)을 얻었다.31.5 g of (S) -5- [2- (2-ethoxyphenoxy) acetamino-3-iodine] propyl-2-methoxybenzenesulfonamide obtained in Preparation Example 1, 500 ml of anhydrous tetrahydrofuran, zinc 11.5 g, 4.65 ml of acetic acid was added thereto, followed by stirring under reflux for 30 minutes. The reaction solution was filtered through celite and washed with 150 ml of chloroform. The filtrate was concentrated, 300 ml of 10% aqueous hydrochloric acid was added thereto, extracted twice with 300 ml of chloroform, dried and concentrated. The concentrate was recrystallized with isopropyl alcohol to give (R) -5- [2- (2- 22.1 g (yield: 91%) of methoxyphenoxy) acetamino] propyl-2-methoxybenzenesulfonamide were obtained.
수득된 화합물의 mp와 NMR 데이터는 다음과 같다.Mp and NMR data of the obtained compound are as follows.
mp : 147-151℃mp: 147-151 ℃
1H-NMR(CDCl3) δ: 1.20(3H, d), 1.45(3H, t), 2.70~2.90(2H, dd), 4.00(3H, s) 4.10(2H, q), 4.30(1H, m), 4.50(2H, S) 5.05(2H, S) 1 H-NMR (CDCl 3 ) δ: 1.20 (3H, d), 1.45 (3H, t), 2.70-2.90 (2H, dd), 4.00 (3H, s) 4.10 (2H, q), 4.30 (1H, m), 4.50 (2H, S) 5.05 (2H, S)
<실시예 2><Example 2>
상기 제조예 2에서 수득한 (S)-5-[2-(2-에톡시페녹시)아세트아미노-3-클로로]프로필-2-메톡시벤젠설폰아미드 8.2g, 헥사메칠포스포트리아미드 50ml, 소디움보로하이드라이드 2.71g을 넣고 70~80℃에서 2시간동안 가온반응하였다. 냉각한 후 서서히 5% 염산 수용액 100ml을 서서히 가하고 클로르포름 100ml로 2회 추출한 다음 건조, 농축하였으며, 상기 농축물을 이소프로필알코올로 재결정하여 화학식 1의 (R)-5-[2-(2-에톡시페녹시)아세트아미노]프로필-2-메톡시벤젠설폰아미드 5.08g(수율:67%)을 얻었다. 수득된 화합물의 mp와 NMR 데이터는 상기 실시예 1의 결과와 동일하다.8.2 g of (S) -5- [2- (2-ethoxyphenoxy) acetamino-3-chloro] propyl-2-methoxybenzenesulfonamide obtained in Preparation Example 2, 50 ml of hexamethylphosphotriamide, 2.71 g of sodium borohydride was added thereto, followed by warming at 70 to 80 ° C. for 2 hours. After cooling, 100 ml of 5% aqueous hydrochloric acid solution was slowly added, extracted twice with 100 ml of chloroform, dried, and concentrated. The concentrate was recrystallized with isopropyl alcohol (R) -5- [2- (2- 5.08 g (yield: 67%) of ethoxyphenoxy) acetamino] propyl-2-methoxybenzenesulfonamide was obtained. Mp and NMR data of the obtained compound are the same as in Example 1 above.
상기 실시예 1과 실시예 2에서 보는 바와 같이 본 발명에 의해 화학식 1의 페녹시아세트아미드 유도체 화합물을 제조할 경우 간단한 반응공정을 통해 높은 수율로 페녹시아세트아미드 유도체를 제조할 수 있게 된다.When the phenoxyacetamide derivative compound of Chemical Formula 1 is prepared according to the present invention as shown in Examples 1 and 2, it is possible to prepare the phenoxyacetamide derivative in a high yield through a simple reaction process.
상기에서 설명한 바와 같이 본 발명에 따른 방법에 의해 화학식 1의 페녹시아세트아미드 유도체를 제조할 경우 반응공정 중 부반응을 수반하지 않아 부산물의 발생을 최소화 할 수 있을 뿐만 아니라 고수율로 화학식 1의 화합물을 수득할 수 있어 매우 경제적인 효과가 있다.As described above, when the phenoxyacetamide derivative of Formula 1 is prepared by the method according to the present invention, it does not involve side reactions during the reaction process, thereby minimizing the generation of by-products and high yield of the compound of Formula 1 It can be obtained and has a very economic effect.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2002-0044333A KR100466693B1 (en) | 2002-07-26 | 2002-07-26 | A preparing process of phenoxyacetamide derivative |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2002-0044333A KR100466693B1 (en) | 2002-07-26 | 2002-07-26 | A preparing process of phenoxyacetamide derivative |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040009950A KR20040009950A (en) | 2004-01-31 |
| KR100466693B1 true KR100466693B1 (en) | 2005-01-15 |
Family
ID=37318798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2002-0044333A KR100466693B1 (en) | 2002-07-26 | 2002-07-26 | A preparing process of phenoxyacetamide derivative |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100466693B1 (en) |
-
2002
- 2002-07-26 KR KR10-2002-0044333A patent/KR100466693B1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040009950A (en) | 2004-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101718173B1 (en) | Method for producing phenylacetamide compound | |
| KR100466693B1 (en) | A preparing process of phenoxyacetamide derivative | |
| MX2014009309A (en) | Method for preparing compound by novel michael addition reaction using water or various acids as additive. | |
| JP3831954B2 (en) | Process for producing 4-hydroxy-2-pyrrolidone | |
| JP2003335735A (en) | Method for producing perfluoroisopropylanilines | |
| JP3146596B2 (en) | Method for producing 3-hydroxymethyl-1-propargylimidazolidine-2,4-dione | |
| JP2018505179A (en) | Process for the preparation of compounds such as 3-arylbutanal useful for the synthesis of medetomidine | |
| KR100466079B1 (en) | A preparing process of phenoxyacetamide derivative | |
| JP2004528380A (en) | Method for producing zolpidem | |
| EP2980079A1 (en) | Method of manufacturing pyridazinone compound | |
| KR100311949B1 (en) | Process for the preparation of 1-[(cyclopent-3-en-1-yl)methyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione | |
| KR100405090B1 (en) | Preparation of phenethylamine derivatives | |
| JPH07316137A (en) | Production of (hexahydro-1-methyl-1h-azepin-4-yl)-hydrazine or salt thereof | |
| KR100335852B1 (en) | A preparing process of phenylacetoxyacetic acid derivatives | |
| JPS58135843A (en) | Intermediate for 4-phenyl-1,3-benzodiazepine and manufacture | |
| JP3898258B2 (en) | Method for producing 3-alkylflavanonol derivative | |
| JP2013035854A (en) | Method for producing tetrahydropyran compound | |
| JPH11171876A (en) | Production of 2,4-oxazolidinediones | |
| JP2000063321A (en) | Production of long-chain beta-hydroxycarboxylic acid of high optical purity | |
| WO2014031581A1 (en) | Process for the synthesis of substituted gamma lactams | |
| JPH0952855A (en) | Production of 9-fluorenylmethanols | |
| JPH10120674A (en) | Production of 2-methyl-3-(3,4-methylenedioxyphenyl) acrylic aldehyde | |
| JP3013760B2 (en) | Method for producing 4-hydroxy-2-pyrrolidone | |
| JP2009215198A (en) | METHOD FOR PRODUCING OPTICALLY ACTIVE beta-FLUOROMETHYLCARBONYL DERIVATIVE | |
| JP2004026652A (en) | beta-ALKOXYACRYLONITRILE DERIVATIVE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20121210 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20131211 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20141210 Year of fee payment: 11 |
|
| LAPS | Lapse due to unpaid annual fee |